Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.09 USD | +14.45% | +14.72% | -43.42% |
Capitalization | 770M 733M 682M 608M 1.08B 65.24B 1.19B 8.49B 3.15B 26.75B 2.89B 2.83B 115B | P/E ratio 2024 * |
-8.11x | P/E ratio 2025 * | 10.9x |
---|---|---|---|---|---|
Enterprise value | 887M 844M 786M 701M 1.25B 75.17B 1.37B 9.78B 3.62B 30.83B 3.33B 3.26B 133B | EV / Sales 2024 * |
1.28x | EV / Sales 2025 * | 1.12x |
Free-Float |
96.11% | Yield 2024 * |
-
| Yield 2025 * | - |
Last Transcript: Pacira BioSciences, Inc.
1 day | -6.34% | ||
1 week | -0.60% | ||
Current month | -1.36% | ||
1 month | +0.66% | ||
3 months | +9.88% | ||
6 months | -46.00% | ||
Current year | -50.56% |
Director | Title | Age | Since |
---|---|---|---|
Frank Lee
CEO | Chief Executive Officer | 56 | 2024-01-01 |
Shawn Cross
DFI | Director of Finance/CFO | 56 | 2024-10-20 |
Daryl Gaugler
COO | Chief Operating Officer | 62 | 2022-05-03 |
Manager | Title | Age | Since |
---|---|---|---|
Andreas Wicki
BRD | Director/Board Member | 65 | 2006-11-30 |
Laura Brege
BRD | Director/Board Member | 66 | 2011-06-01 |
Paul Hastings
CHM | Chairman | 64 | 2024-01-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.24% | 26 M€ | +10.41% | - |
Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
---|---|---|---|---|---|---|
-6.34% | -0.60% | -40.02% | -68.25% | 770M | ||
+1.69% | +3.04% | +39.26% | +231.19% | 732B | ||
-0.60% | +4.41% | +12.14% | +119.08% | 488B | ||
-1.58% | -1.40% | -3.80% | -4.40% | 367B | ||
-0.15% | +0.20% | +26.56% | +52.71% | 321B | ||
+1.23% | +0.23% | -1.56% | +38.87% | 258B | ||
-0.35% | +0.51% | +3.05% | -30.95% | 231B | ||
-2.13% | -1.84% | +5.69% | +21.99% | 210B | ||
-2.51% | -0.25% | +2.34% | +25.62% | 212B | ||
+0.08% | -0.60% | +2.15% | +37.48% | 150B | ||
Average | -1.10% | +0.44% | +4.58% | +42.34% | 296.78B | |
Weighted average by Cap. | -0.40% | +1.24% | +14.85% | +87.99% |
2024 * | 2025 * | |
---|---|---|
Net sales | 692M 658M 613M 546M 973M 58.6B 1.07B 7.62B 2.83B 24.03B 2.6B 2.54B 103B | 646M 614M 572M 510M 908M 54.7B 997M 7.11B 2.64B 22.43B 2.43B 2.37B 96.55B |
Net income | -5.13M -4.88M -4.55M -4.05M -7.22M -435M -7.92M -56.52M -20.96M -178M -19.28M -18.85M -767M | 55.47M 52.77M 49.15M 43.81M 78.03M 4.7B 85.66M 611M 227M 1.93B 208M 204M 8.29B |
Net Debt | 117M 112M 104M 92.58M 165M 9.93B 181M 1.29B 479M 4.07B 440M 431M 17.53B | -45.18M -42.98M -40.03M -35.68M -63.55M -3.83B -69.77M -498M -185M -1.57B -170M -166M -6.75B |
Date | Price | Change | Volume |
---|---|---|---|
24-12-04 | 19.09 $ | +14.45% | 1,655,537 |
24-12-03 | 16.68 $ | -6.34% | 1,419,812 |
24-12-02 | 17.81 $ | +5.32% | 589,191 |
24-11-29 | 16.91 $ | +1.62% | 296,431 |
24-11-27 | 16.64 $ | -0.83% | 487,708 |
Delayed Quote Nasdaq, December 03, 2024 at 04:00 pm EST
More quotesQuarterly revenue - Rate of surprise
- Stock Market
- Equities
- PCRX Stock